The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspectives.

Manfredi Rizzo, Dragana Nikolic, Giuseppe Montalto, Maciej Banach, Ali A. Rizvi, Manfredi Rizzo

Risultato della ricerca: Article

17 Citazioni (Scopus)

Abstract

Glucagon-like peptide-1 is an incretin secreted in response to nutrient ingestion. Derangements in the incretinsystem may contribute to the onset and progression of hyperglycemia in Type 2 diabetes. Liraglutide is a long-actinghuman glucagon-like peptide-1-receptor agonist suitable for once-daily administration. Blood glucose- and weightreducingeffects, improvements in pancreatic b-cell function and a low risk of hypoglycemic events have beendemonstrated with this agent. There is a trend towards improvement in the proinflammatory milieu. Liraglutidealso appears to have beneficial effects on plasma lipids and lipoproteins in the form of a reduction in total cholesterol,triglycerides and LDL cholesterol, and a concomitant increase in HDL cholesterol. These favorable effects ofliraglutide on multiple metabolic pathways may contribute to a retardation of atherosclerosis and possibly a reductionin cardiovascular risk. However, prospective studies are still needed to elucidate the clinical impact of liraglutideon cardiovascular outcomes in patients with Type 2 diabetes
Lingua originaleEnglish
pagine (da-a)173-181
Numero di pagine9
RivistaClinical Lipidology
Volume8
Stato di pubblicazionePublished - 2013

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cita questo